Related topics

Sangamo: 3Q Earnings Snapshot

November 6, 2019 GMT

RICHMOND, Calif. (AP) _ Sangamo Therapeutics Inc. (SGMO) on Wednesday reported a loss of $27.3 million in its third quarter.

The Richmond, California-based company said it had a loss of 24 cents per share.

The results beat Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss of 33 cents per share.

The drug developer posted revenue of $22 million in the period, also surpassing Street forecasts. Four analysts surveyed by Zacks expected $14 million.

Sangamo shares have fallen 17% since the beginning of the year. In the final minutes of trading on Wednesday, shares hit $9.50, a fall of 31% in the last 12 months.


This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on SGMO at https://www.zacks.com/ap/SGMO